Centre Hospitalier Universitaire de Grenoble
Grenoble, 38043, France
NCT Number: NCT00800995
INTRODUCTION:
Acting directly on the anti-radical enzyme chain, the superoxide dismutase (SOD), a major enzyme of the anti-oxidant system, provides an alternative of the antioxidants treatment in ARMD. Its synthesis depends on the cellular oxygenated reactive species, and leads to the conversion of the superoxide ion (O2-) into hydrogen peroxide (H2O2). This compound is the cell watch guard continuously regulating a free radicals' detoxifying chain. Subsequently, by increasing the production of H2O2, the administration of SOD can trigger endogenous/internal antioxidant mechanisms.
Oral administration of SOD is possible in its galenic form, Glisodine. The purpose of this study was to evaluate the protective effect of SOD on the bilateralization of the disease.
Looking for future studies?
Notify MeAll sexes
Interventional
Phase 3
Grenoble, 38043, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 24 months
Centre de Recherche en Nutrition Humaine Rhone-Alpe
Other
SOD as Antioxidant Treatment OF ARMD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02725762
Age Related Macular Degeneration, Eye Diseases
Toronto, Ontario, Canada
View Trial DetailsNCT03076697
Age Related Macular Degeneration, Cardiovascular Diseases
View Trial DetailsNCT07318428
Age Related Macular Degeneration, Cardiovascular Diseases
Busan, South Korea
View Trial DetailsNCT07424235
AMD, Age Related Macular Degeneration
View Trial Details